Last reviewed · How we verify
NCT06578312
"Critical State" Early Warning Score After CHD Surgery and Rapid Response Team
trial in Congenital Heart Disease in 4,115 participants. Completed in 1 July 2024.
1 July 2024
Quick facts
| Lead sponsor | Chinese Academy of Medical Sciences, Fuwai Hospital |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 4,115 |
| Start date | 1 January 2021 |
| Primary completion | 1 July 2024 |
| Estimated completion | 1 July 2024 |
| Sites | 1 location across China |
Conditions studied
- Congenital Heart Disease — all drugs for Congenital Heart Disease →
Sponsor
Chinese Academy of Medical Sciences, Fuwai Hospital
Who can join
Adults 28 Days to 14, any sex, with Congenital Heart Disease. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
By establishing a warning scoring tool for the early \"critical state\" after congenital heart disease surgery, the multidisciplinary rapid response team is proactively activated, forming an integrated treatment model of early warning-team decision-making-organ assistance.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06578312
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Congenital Heart Disease
Currently open trials in the same condition.
- NCT07193719 — Influence of Personalized Lung Volume Optimization Maneuver on Lung Function and Cardiac Performance in Children · Phase 1, PHASE2 · recruiting
- NCT07023367 — Parent Navigator Program (PNP) to Improve Outcomes in Latino/x Children and Parents · NA · recruiting
- NCT06833320 — Propranolol Treatment for Postoperative Chylothorax · Phase 1, PHASE2 · recruiting
- NCT06668389 — Sodium-Glucose Cotransporter 2 Inhibitors for Repaired Tetralogy of Fallot Patients for Enhancement of Cardio-Pulmonary · Phase 4 · recruiting
- NCT06872320 — The Influence of Probiotics on Metabolome and Heart Rate Variability in Heart Failure of Structure Heart Disease · NA · active not recruiting
Other Chinese Academy of Medical Sciences, Fuwai Hospital trials
Trials by the same sponsor.
- NCT07450196 — A Prospective, Multicenter, Observational Study Evaluating Safety and Effectiveness of SAPIEN 3 Transcatheter Aortic Val · not yet recruiting
- NCT07511309 — FFR-Guided Revascularization in Atherosclerotic Renal Artery Stenosis: A Randomized Controlled Trial · NA · not yet recruiting
- NCT07054541 — A Novel Echocardiography-Guided Strategy for Percutateous Closure of Atrial Septal Defect Assisted by PannaWire · Phase 4 · not yet recruiting
- NCT07458672 — TAVR for Aortic Regurgitation Under TTE Guidance · NA · not yet recruiting
- NCT07462325 — Proteomic and Inflammatory Omics Changes With Colchicine Therapy in Coronary Heart Disease · Phase 4 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06578312 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Chinese Academy of Medical Sciences, Fuwai Hospital
- Last refreshed: 29 August 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06578312.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing